Cancer Research Shows Promise for Reducing Footprint
A significant portion of Alzheimer's research funding and prestige is reportedly tied to the amyloid hypothesis. Reports indicate that many medical examiners who approved Alzheimer's drugs subsequently moved to work for the companies they regulated, raising concerns about regulatory capture within the FDA.
Topics
Developing
- 891d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 891d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 891d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 891d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
WBUR Boston
“importance of the amyloid hypothesis. Their money, their prestige, their career aspirations are all tied up with that. You write that 11 of 16 FDA medical examiners who worked on drug approvals left to become employees or consultants for the companies that they just regulated.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade